Antibiotics Need Additional Development Incentives, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Director Woodcock tells House panel that a guidance clarifying trial designs is not enough, an acknowledgement a Cubist executive calls a "break-through."
You may also be interested in...
Antibiotics Need "Societal Class" Designation To Improve Discovery, Discourage Use, Tufts Professor Tells Congress
As part of its effort to encourage the development and preservation of antibiotics, FDA should consider classifying them separately from other drugs, one scientist argued
Antibiotics Need "Societal Class" Designation To Improve Discovery, Discourage Use, Tufts Professor Tells Congress
As part of its effort to encourage the development and preservation of antibiotics, FDA should consider classifying them separately from other drugs, one scientist argued
Industry Should Monitor Quality Outside Factory To Fight Drug Resistance
Pharmaceutical manufacturers have to better ensure the quality and security of their supply chains, as well as develop new drugs, to win the fight against antibiotic resistance, according to the Center for Global Development